A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma

References

• Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, et al. The human vaccines project: A roadmap for cancer vaccine development. Sci Transl Med. 2016;8:334ps9–ps9. doi:10.1126/scitranslmed.aaf0685. PMID:27075624
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. doi:10.1038/nature12477. PMID:23945592
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26. doi:10.1056/NEJMoa1104621. PMID:21639810
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. doi:10.1056/NEJMoa1200690. PMID:22658127
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65. doi:10.1056/NEJMoa1200694. PMID:22658128
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi F. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:133–44. doi:10.1056/NEJMoa1305133.
   Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99. doi:10.1056/NEJMoa1406498. PMID:25409260
   PubMed Web of Science ®Google Scholar
• Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3:399–411. doi:10.1158/2326-6066.CIR-14-0215. PMID:25678581
   PubMed Web of Science ®Google Scholar
• Agha-Mohammadi S, Lotze MT. Immunomodulation of cancer: Potential use of selectively replicating agents. J Clin Invest. 2000;105:1173–6. doi:10.1172/JCI10026. PMID:10791989
   PubMed Web of Science ®Google Scholar
• Barouch DH, Letvin NI, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev. 2014;202:266–74. doi:10.1111/j.0105-2896.2004.00200.x.
   Google Scholar
• Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539–43. doi:10.1073/pnas.90.8.3539. PMID:8097319
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, DePriest C, McClay EF, Amatruda TT, de Leon C, Ellis RE, Mayorga C, Carbonell D, Cubellis JM. Tumor stem cell antigens as consolidative active specific immunotherapy: A randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother. 2012;35:641–9. doi:10.1097/CJI.0b013e31826f79c8. PMID:22996370
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–71. doi:10.1200/JCO.2009.24.3675. PMID:19884534
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119–27. doi:10.1056/NEJMoa1012863. PMID:21631324
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunostimulatory cytokines. Oncoimmunology. 2013;2:e24850. doi:10.4161/onci.24850. PMID:24073369
   PubMed Web of Science ®Google Scholar
• de Gast G, Klümpen H-J, Vyth-Dreese F, Kersten M-J, Verra N, Sein J, Batchelor D, Nooijen WJ, Schornagel JH. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res. 2000;6:1267–72. PMID:10778950
   PubMed Web of Science ®Google Scholar
• Lotze MT. Cytokines in the treatment of cancer. In: Caligiuri MA, Lotze MT, editors. Cytokines in the genesis and treatment of cancer. Totowa (New Jersey): Humana Press; 2007. p. 307–471.
   Google Scholar
• Sivapalasingam S, Kennedy JS, Borkowsky W, Valentine F, Zhan MX, Pazoles P, Paolino A, Ennis FA, Steigbigel NH. Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus. J Infect Dis. 2007;195:1151–9. doi:10.1086/512161. PMID:17357051
   PubMed Web of Science ®Google Scholar
• Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28:710–22. doi:10.1016/j.immuni.2008.02.020. PMID:18468462
   PubMed Web of Science ®Google Scholar
• Yamane H, Paul WE. Cytokines of the gamma(c) family control CD4+ T cell differentiation and function. Nat Immunol. 2012;13:1037–44. doi:10.1038/ni.2431. PMID:23080204
   PubMed Web of Science ®Google Scholar
• Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity. 2012;36:142–52. doi:10.1016/j.immuni.2012.01.002. PMID:22265676
   PubMed Web of Science ®Google Scholar
• Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69:3077–85. doi:10.1158/0008-5472.CAN-08-2281. PMID:19293190
   PubMed Web of Science ®Google Scholar
• Valentine FT, Lawrence HS. Lymphocyte stimulation: Transfer of cellular hypersensitivity to antigen in vitro. Science. 1969;165:1014–6. doi:10.1126/science.165.3897.1014. PMID:5804724
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71. doi:10.1038/nature13954. PMID:25428505
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–5. doi:10.1038/nature14404. PMID:25970248
   PubMed Web of Science ®Google Scholar
• Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity. 2013;39:11–26. doi:10.1016/j.immuni.2013.07.008. PMID:23890060
   PubMed Web of Science ®Google Scholar
• Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827–37. doi:10.1158/2159-8290.CD-15-1545. PMID:27301722
   PubMed Web of Science ®Google Scholar
• Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9:eaah3560. doi:10.1126/scitranslmed.aah3560. PMID:28251903
   PubMed Web of Science ®Google Scholar
• Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6:226ra32. doi:10.1126/scitranslmed.3008095. PMID:24598590
   PubMed Web of Science ®Google Scholar
• Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11:1018–30. doi:10.1016/j.celrep.2015.04.031. PMID:25959818
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. doi:10.1093/jnci/92.3.205. PMID:10655437
   PubMed Web of Science ®Google Scholar
• Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6:202–16. doi:10.1158/2159-8290.CD-15-0283. PMID:26645196
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–70. doi:10.1126/science.1203486. PMID:21436444
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–22. doi:10.1038/ni.2703. PMID:24048123
   PubMed Web of Science ®Google Scholar
• deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: A critical review of the literature. Clin Cancer Res. 2012;18:3022–9. doi:10.1158/1078-0432.CCR-11-3216. PMID:22510350
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidlines for the evaluation of immune therapy in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. doi:10.1158/1078-0432.CCR-09-1624. PMID:19934295
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8. doi:10.1200/JCO.2014.58.3377. PMID:26014293
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, et al. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer. 2016;4:12. doi:10.1186/s40425-016-0116-2. PMID:26981242
   PubMed Web of Science ®Google Scholar
• Weide B, Eigentler TK, Pflugfelder A, Leiter U, Meier F, Bauer J, Schmidt D, Radny P, Pföhler C, Garbe C. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother. 2011;60:487–93. doi:10.1007/s00262-010-0957-3. PMID:21174093
   PubMed Web of Science ®Google Scholar
• Byers BA, Temple-Oberle CF, Hurdle V, McKinnon JG. Treatment of in-transit melanoma with intra-lesional interleukin-2: A systematic review. J Surg Oncol. 2014;110:770–5. doi:10.1002/jso.23702. PMID:24996052
   PubMed Web of Science ®Google Scholar
• Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood. 2015;125:2079–86. doi:10.1182/blood-2014-08-593137. PMID:25662332
   PubMed Web of Science ®Google Scholar
• Mier JW, Vachino G, Vandermeer JWM, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA. Induction of circulating tumor necrosis factor (Tnf-Alpha) as the mechanism for the febrile response to interleukin-2 (Il-2) in cancer-patients. J Clin Immunol. 1988;8:426–36. doi:10.1007/BF00916947. PMID:3265420
   PubMed Web of Science ®Google Scholar
• Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity. 1995;2:331. doi:10.1016/1074-7613(95)90141-8. PMID:7719938
   PubMed Web of Science ®Google Scholar
• Prlic M, Lefrancois L, Jameson SC. Multiple choices: Regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. J Exp Med. 2002;195:F49–52. doi:10.1084/jem.20020767. PMID:12070294
   PubMed Web of Science ®Google Scholar
• Hamilton SE, Prlic M, Jameson SC. Environmental conservation: Bystander CD4 T cells keep CD8 memories fresh. Nat Immunol. 2004;5:873–4. doi:10.1038/ni0904-873. PMID:15334079
   PubMed Web of Science ®Google Scholar
• Shrikant P, Mescher MF. Opposing effects of IL-2 in tumor immunotherapy: Promoting CD8 T cell growth and inducing apoptosis. J Immunol. 2002;169:1753–9. doi:10.4049/jimmunol.169.4.1753. PMID:12165496
   PubMed Web of Science ®Google Scholar
• Arneja A, Johnson H, Gabrovsek L, Lauffenburger DA, White FM. Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J Immunol. 2014;192:123–35. doi:10.4049/jimmunol.1302291. PMID:24298013
   PubMed Web of Science ®Google Scholar
• Ring AM, Lin JX, Feng D, Mitra S, Rickert M, Bowman GR, Pande VS, Li P, Moraga I, Spolski R, et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol. 2012;13:1187–95. doi:10.1038/ni.2449. PMID:23104097
   PubMed Web of Science ®Google Scholar
• Bezbradica JS, Rosenstein RK, Demarco RA, Brodsky I, Medzhitov R. A role for the ITAM signaling module in specifying cytokine-receptor functions. Nat Immunol. 2014;15:333–42. doi:10.1038/ni.2845. PMID:24608040
   PubMed Web of Science ®Google Scholar
• Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201:139–48. doi:10.1084/jem.20041057. PMID:15630141
   PubMed Web of Science ®Google Scholar
• Yamane H, Paul WE. Cytokines of the gamma(c) family control CD4+ T cell differentiation and function. Nat Immunol. 2012;13:1037–44. doi:10.1038/ni.2431. PMID:23080204
   PubMed Web of Science ®Google Scholar
• Wan YY, Flavell RA. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev. 2006;212:114–30. doi:10.1111/j.0105-2896.2006.00407.x. PMID:16903910
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9:e87705. doi:10.1371/journal.pone.0087705. PMID:24498358
   PubMed Web of Science ®Google Scholar
• Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011;17:4101–9. doi:10.1158/1078-0432.CCR-11-0407. PMID:21558401
   PubMed Web of Science ®Google Scholar
• Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJ, van der Burg S, Kapiteijn E, Michielin O, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6:254ra128. doi:10.1126/scitranslmed.3008918. PMID:25232180
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30. doi:10.1200/JCO.2013.53.0105. PMID:24590637
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17. doi:10.1056/NEJMoa1414428. PMID:25891304
   PubMed Web of Science ®Google Scholar
• van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31:e439–42. doi:10.1200/JCO.2012.47.7521. PMID:24043743
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577–81. doi:10.1038/nature13988. PMID:25428507
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol. 2011;104:379–85. doi:10.1002/jso.21876. PMID:21858832
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988;48:5883–93. PMID:3262416
   PubMed Web of Science ®Google Scholar